Byron Robinson - 01 Mar 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Strategy Officer
Signature
/s/ Maria Dobek, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
03 Mar 2022, 16:06:10 UTC
Next filing
05 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +230,000 $0.000000 230,000 01 Mar 2022 Common Stock 230,000 $16.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on February 28, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.